pmid	doi	year	title	Hugo_Symbol
32431543	10.2147/CMAR.S242903	2022	Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population.	JAK3
32695399	10.1186/s40364-020-00205-4	2022	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	JAK3
33526873	10.1038/s41379-021-00739-4	2022	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.	JAK3
34321240	10.1158/0008-5472.CAN-21-1027	2022	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL.	JAK3
34465864	10.1038/s41375-021-01392-1	2022	PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.	JAK3
34547646	10.1016/j.bioorg.2021.105330	2022	Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.	JAK3
34895266	10.1186/s13000-021-01173-5	2022	Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.	JAK3
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	JAK3
35111674	10.3389/fonc.2021.790481	2022	Mutations in <i>JAK/STAT</i> and <i>NOTCH1</i> Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders.	JAK3
35253299	10.1002/gcc.23036	2022	CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.	JAK3
35395675	10.1093/carcin/bgac034	2022	Genomic profile of radiation-induced early-onset mouse B-cell lymphoma recapitulates features of Philadelphia chromosome-like acute lymphoblastic leukemia in humans.	JAK3
35411095	10.1038/s41375-022-01558-5	2022	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.	JAK3
35511669	10.3324/haematol.2021.280349	2022	Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T-cell lymphoma.	JAK3
35551151	10.1097/PAS.0000000000001914	2022	Targeted Next-generation Sequencing Reveals a Wide Morphologic and Immunophenotypic Spectrum of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma.	JAK3
35685993	10.21147/j.issn.1000-9604.2022.02.03	2022	Genomic landscape of T-cell lymphoblastic lymphoma.	JAK3
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	JAK3
35734596	10.3389/fonc.2022.846573	2022	The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.	JAK3
35803438	10.1016/j.taap.2022.116156	2022	1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells.	JAK3
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	JAK3
35920299	10.1096/fj.202200061RR	2022	Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context.	JAK3
23136597	10.3892/etm_00000014	2021	Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model.	JAK3
28123872	10.1080/2162402X.2016.1237327	2021	IL-15 enhances the antitumor effect of human antigen-specific CD8<sup>+</sup> T cells by cellular senescence delay.	JAK3
31049933	10.1111/bjd.18098	2021	Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.	JAK3
31822801	10.1038/s41379-019-0415-5	2021	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.	JAK3
31918398	10.1016/j.bioorg.2019.103542	2021	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.	JAK3
32558259	10.1111/jcmm.15362	2021	Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.	JAK3
32843425	10.1101/mcs.a004994	2021	Failure of tofacitinib to achieve an objective response in a <i>DDX3X-MLLT10</i> T-lymphoblastic leukemia with activating <i>JAK3</i> mutations.	JAK3
33376237	10.1038/s41392-020-00331-3	2021	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	JAK3
33466582	10.3390/cancers13020280	2021	JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).	JAK3
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	JAK3
34391330	10.5070/D327754365	2021	Significant improvement of dermatitis herpetiformis with tofacitinib.	JAK3
34623329	10.1172/JCI152464	2021	To T or not to B: germline RUNX1 mutation preferences in pediatric ALL predisposition.	JAK3
30914738	10.1038/s41598-019-41675-3	2020	Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma.	JAK3
30997845	10.1080/10428194.2019.1594220	2020	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.	JAK3
31313387	10.1002/JLB.5RU0519-145R	2020	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.	JAK3
31492675	10.1182/blood.2019000015	2020	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.	JAK3
31545408	10.3892/ijo.2019.4882	2020	Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.	JAK3
31570576	10.1073/pnas.1901382116	2020	IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies.	JAK3
31773249	10.1007/s00428-019-02704-8	2020	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.	JAK3
31799703	10.1111/cei.13405	2020	The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype.	JAK3
31896782	10.1038/s41375-019-0697-0	2020	The clinical mutatome of core binding factor leukemia.	JAK3
31914529	10.3760/cma.j.issn.0529-5807.2020.01.004	2020	[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases].	JAK3
31992840	10.1038/s41375-019-0685-4	2020	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.	JAK3
32188095	10.3390/cancers12030702	2020	<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL.	JAK3
32316399	10.3390/cancers12040986	2020	Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing.	JAK3
32631903	10.1128/MCB.00189-20	2020	Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.	JAK3
32922661	10.18632/oncotarget.27683	2020	The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL).	JAK3
33102814	10.1016/j.bbrep.2020.100832	2020	Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sézary cells.	JAK3
33283700	10.19746/j.cnki.issn.1009-2137.2020.06.001	2020	[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing].	JAK3
27669408	10.1371/journal.pone.0163011	2019	Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.	JAK3
28356009	10.2174/1871520617666170327115657	2019	ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.	JAK3
29187379	10.1182/blood-2017-07-797597	2019	Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.	JAK3
29262599	10.18632/oncotarget.21790	2019	Fusion of the genes ataxin 2 like, <i>ATXN2L</i>, and Janus kinase 2, <i>JAK2</i>, in cutaneous CD4 positive T-cell lymphoma.	JAK3
29434279	10.1038/s41375-017-0004-x	2019	Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.	JAK3
29496663	10.1158/2159-8290.CD-17-0583	2019	HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.	JAK3
29751003	10.1016/j.jid.2018.03.1526	2019	SATB1 in Malignant T Cells.	JAK3
29986854	10.1182/bloodadvances.2018016089	2019	Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.	JAK3
30054295	10.1182/blood-2018-01-829424	2019	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.	JAK3
30218753	10.1016/j.humpath.2018.08.025	2019	Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.	JAK3
30402490	10.1155/2018/6728128	2019	Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.	JAK3
30420593	10.1038/s41408-018-0138-8	2019	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.	JAK3
30671064	10.3389/fimmu.2018.03108	2019	Loss of JAK1 Drives Innate Immune Deficiency.	JAK3
31002364	10.3892/or.2019.7112	2019	JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type.	JAK3
27144517	10.18632/oncotarget.9077	2018	Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.	JAK3
27329723	10.18632/oncotarget.10160	2018	STAT5 induces miR-21 expression in cutaneous T cell lymphoma.	JAK3
27600764	10.1038/ncomms12602	2018	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	JAK3
27602765	10.18632/oncotarget.11796	2018	Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.	JAK3
27732937	10.18632/oncotarget.12529	2018	Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.	JAK3
28214593	10.1016/j.mce.2017.02.019	2018	JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.	JAK3
29146136	10.1016/j.ejmech.2017.10.080	2018	Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.	JAK3
29293620	10.1371/journal.pone.0190468	2018	Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma.	JAK3
29454012	10.1016/j.yrtph.2018.02.006	2018	Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.	JAK3
30257940	10.1073/pnas.1721678115	2018	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.	JAK3
26854024	10.1038/leu.2016.13	2017	JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.	JAK3
27151989	10.3324/haematol.2016.143875	2017	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.	JAK3
27164089	10.3390/ijms17050683	2017	Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.	JAK3
27174491	10.1038/leu.2016.83	2017	MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.	JAK3
27297789	10.1182/blood-2016-01-690701	2017	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.	JAK3
27997540	10.1371/journal.pmed.1002200	2017	IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.	JAK3
28009988	10.18632/oncotarget.14032	2017	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.	JAK3
28245838	10.1186/s13045-017-0431-1	2017	Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.	JAK3
28284718	10.1016/j.ajpath.2017.01.004	2017	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.	JAK3
28315597	10.1016/j.ejmech.2017.03.001	2017	Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.	JAK3
28359267	10.1186/s12885-017-3233-5	2017	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	JAK3
28424246	10.1084/jem.20160894	2017	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.	JAK3
28671688	10.1038/ng.3909	2017	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.	JAK3
25146434	10.3109/10428194.2014.957204	2016	Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.	JAK3
25915535	10.18632/oncotarget.3837	2016	Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.	JAK3
25961555	10.2741/4369	2016	ALK-mediated post-transcriptional regulation: focus on RNA-binding proteins.	JAK3
25980440	10.18632/oncotarget.3776	2016	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.	JAK3
26169955	10.1016/j.exphem.2015.06.303	2016	A new ATL xenograft model and evaluation of pyrrolidine dithiocarbamate as a potential ATL therapeutic agent.	JAK3
26206799	10.3324/haematol.2015.130179	2016	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.	JAK3
26208852	10.1186/s13045-015-0192-7	2016	JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.	JAK3
26244872	10.18632/oncotarget.4111	2016	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.	JAK3
26269126	10.1186/s12885-015-1586-1	2016	Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.	JAK3
26379152	10.1097/PAS.0000000000000503	2016	Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.	JAK3
26408659	10.1158/2159-8290.CD-15-0892	2016	Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.	JAK3
26415585	10.1038/ncomms9470	2016	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.	JAK3
26446793	10.1074/jbc.M115.670224	2016	Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.	JAK3
26536348	10.1371/journal.pone.0141906	2016	Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.	JAK3
26565811	10.18632/oncotarget.6300	2016	Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.	JAK3
26738536	10.1182/blood-2015-08-662353	2016	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.	JAK3
26859781	10.1016/j.leukres.2016.01.011	2016	A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma.	JAK3
26885984	10.1007/s11010-016-2665-6	2016	Response of the JAK-STAT pathway to mammalian hibernation in 13-lined ground squirrel striated muscle.	JAK3
26917488	10.1111/bjh.13952	2016	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.	JAK3
26974155	10.1172/JCI81468	2016	LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.	JAK3
23808814	10.3109/10428194.2013.819577	2015	Rare occurrence of JAK3 mutations in natural killer cell neoplasms in Japan.	JAK3
24621498	10.4161/cc.28256	2015	IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).	JAK3
24837469	10.3324/haematol.2014.108142	2015	A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.	JAK3
24965108	10.1111/pin.12166	2015	Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.	JAK3
25430085	10.1007/s12185-014-1711-y	2015	Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.	JAK3
25485578	10.4161/15384101.2014.965061	2015	Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.	JAK3
25595890	10.18632/oncotarget.2218	2015	Mutational spectrum of adult T-ALL.	JAK3
26082451	10.1182/blood-2014-11-611194	2015	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.	JAK3
23689514	10.1038/leu.2013.157	2014	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.	JAK3
23934551	10.1007/s00232-013-9582-3	2014	Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.	JAK3
24153015	10.1038/leu.2013.309	2014	Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies.	JAK3
24523507	10.4049/jimmunol.1302951	2014	Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.	JAK3
24550509	10.1073/pnas.1301138111	2014	Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression.	JAK3
24689848	10.1111/cas.12408	2014	Disease-specific mutations in mature lymphoid neoplasms: recent advances.	JAK3
24726056	10.1016/j.ejca.2014.03.004	2014	Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.	JAK3
24879792	10.4049/jimmunol.1303184	2014	BCL6 controls Th9 cell development by repressing Il9 transcription.	JAK3
25057888	10.1042/BJ20140712	2014	The molecular regulation of Janus kinase (JAK) activation.	JAK3
23028900	10.1371/journal.pone.0045274	2013	Innate immunity and non-Hodgkin's lymphoma (NHL) related genes in a nested case-control study for gastric cancer risk.	JAK3
23066158	10.4049/jimmunol.1201440	2013	Highly restricted usage of Ig H chain VH14 family gene segments in Slp65-deficient pre-B cell leukemia in mice.	JAK3
23348693	10.1016/j.canlet.2012.12.022	2013	Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate.	JAK3
23610619	10.1177/2040620712471553	2013	The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.	JAK3
23768868	10.1016/j.leukres.2013.05.003	2013	Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.	JAK3
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	JAK3
22368272	10.1182/blood-2011-11-394221	2012	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.	JAK3
22425895	10.1038/leu.2012.74	2012	Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.	JAK3
22524835	10.7314/apjcp.2012.13.2.621	2012	Genetic variants in interleukin-2 and risk of lymphoma among children in Korea.	JAK3
22527961	10.1007/s10822-012-9572-z	2012	Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).	JAK3
22675565	10.1371/journal.pone.0038463	2012	High accuracy mutation detection in leukemia on a selected panel of cancer genes.	JAK3
22705984	10.1158/2159-8290.CD-12-0028	2012	Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.	JAK3
20438785	10.1016/j.humimm.2010.04.004	2011	Polymorphisms in innate immunity genes and risk of childhood leukemia.	JAK3
21070101	10.1586/era.10.203	2011	JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.	JAK3
21106989	10.1182/blood-2010-09-305425	2011	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.	JAK3
21346774	10.1038/jid.2011.27	2011	Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.	JAK3
21499010	10.3858/emm.2011.43.5.035	2011	Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.	JAK3
21537335	10.1038/leu.2011.86	2011	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.	JAK3
21599579	10.3109/10428194.2011.574757	2011	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.	JAK3
21604762	10.1021/jm200326p	2011	Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.	JAK3
21614012	10.1038/jid.2011.129	2011	The role of Jak3 signaling in IL-17 expression in malignant cutaneous T-cell lymphoma.	JAK3
21821710	10.1182/blood-2010-12-319467	2011	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.	JAK3
21892159	10.1038/ng.924	2011	Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.	JAK3
19709433	10.1186/1476-4598-8-67	2010	STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.	JAK3
19747563	10.1016/j.biocel.2009.09.004	2010	JAK3: a two-faced player in hematological disorders.	JAK3
19773279	10.1136/oem.2008.044024	2010	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	JAK3
19793252	10.1111/j.1365-2141.2009.07925.x	2010	MS-1020 is a novel small molecule that selectively inhibits JAK3 activity.	JAK3
20074798	10.1016/j.leukres.2009.12.010	2010	Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo.	JAK3
20193734	10.1016/j.exphem.2010.02.008	2010	Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells.	JAK3
20211620	10.1016/j.febslet.2010.02.071	2010	Uncoupling JAK3 activation induces apoptosis in human lymphoid cancer cells via regulating critical survival pathways.	JAK3
20377589	10.1111/j.1365-2141.2010.08177.x	2010	Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets.	JAK3
20440074	10.1172/JCI41344	2010	IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis.	JAK3
20697856	10.1007/s12185-010-0653-2	2010	Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.	JAK3
20854465	10.1111/j.1600-0463.2010.02669.x	2010	Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis.	JAK3
18769452	10.1038/leu.2008.224	2009	Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.	JAK3
19047679	10.1182/blood-2008-07-166355	2009	BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.	JAK3
19139084	10.1182/blood-2008-06-164368	2009	Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.	JAK3
19139102	10.1074/jbc.M807531200	2009	Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.	JAK3
19470474	10.1073/pnas.0811761106	2009	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	JAK3
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	JAK3
19608866	10.2353/ajpath.2009.080982	2009	IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.	JAK3
18025151	10.1182/blood-2007-06-095182	2008	IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.	JAK3
18281483	10.1158/0008-5472.CAN-07-2403	2008	Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.	JAK3
18297515	10.1080/10428190801895360	2008	JAK and MPL mutations in myeloid malignancies.	JAK3
18633131	10.1182/blood-2007-09-111658	2008	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.	JAK3
18790749	10.1158/1535-7163.MCT-08-0309	2008	A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.	JAK3
17854036	10.1002/jmv.21020	2007	Structural variability of the carboxy-terminus of Epstein-Barr virus encoded latent membrane protein 1 gene in Hodgkin's lymphomas.	JAK3
16170336	10.1038/labinvest.3700348	2006	Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.	JAK3
16554750	10.1038/labinvest.3700393	2006	Jak3 contributes to the activation of ALK and Stat3 in ALK(+) anaplastic large cell lymphoma.	JAK3
16763206	10.1182/blood-2006-04-020305	2006	Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.	JAK3
16825495	10.1182/blood-2006-04-017434	2006	Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.	JAK3
16871283	10.1038/sj.leu.2404323	2006	Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.	JAK3
16932349	10.1038/sj.leu.2404350	2006	Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma.	JAK3
16939498	10.1111/j.1365-2141.2006.06259.x	2006	JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.	JAK3
15621723	10.1080/08977190410001720879	2005	IL-9 and its receptor: from signal transduction to tumorigenesis.	JAK3
15621777	10.1080/10428190400005320	2005	Activation of the Jak3 pathway and myeloid differentiation.	JAK3
15869881	10.1016/j.bmc.2005.04.022	2005	Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling.	JAK3
16048411	10.5858/2005-129-990-ASOTSP	2005	Activation status of the JAK/STAT3 pathway in mantle cell lymphoma.	JAK3
16153455	10.1016/j.humpath.2005.07.011	2005	Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.	JAK3
14565661	10.3109/10428190309178781	2004	The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.	JAK3
14615384	10.1182/blood-2002-12-3861	2004	IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.	JAK3
14630083	10.1016/s0145-2126(03)00158-9	2004	Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.	JAK3
14968112	10.1038/sj.onc.1207398	2004	Identification of NPM-ALK interacting proteins by tandem mass spectrometry.	JAK3
15385932	10.1038/sj.leu.2403495	2004	Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.	JAK3
12389628	10.1080/1042819022386581	2003	Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor.	JAK3
12424201	10.1182/blood-2002-05-1343	2003	NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.	JAK3
12599420		2003	[Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].	JAK3
12613524	10.1080/1042819021000040062	2003	Jak3 expression and genomic sequence in pediatric acute lymphoblastic leukemia.	JAK3
12934099	10.1038/sj.onc.1206849	2003	Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.	JAK3
11739714	10.1128/jvi.76.1.455-459.2002	2002	The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines.	JAK3
11850821	10.1038/sj.onc.1205152	2002	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.	JAK3
12145687	10.1038/sj.leu.2402546	2002	SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.	JAK3
12188892	10.2174/1568009013334287	2002	Structure-based design of novel anticancer agents.	JAK3
11368440	10.1038/sj.leu.2402093	2001	Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.	JAK3
11408795	10.1159/000058523	2001	The role of Epstein-Barr virus in neoplastic transformation.	JAK3
11591117	10.1006/cimm.2001.1829	2001	Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.	JAK3
10707789		2000	T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma.	JAK3
10856136	10.1067/mai.2000.107604	2000	IL-4/IL-13 signaling beyond JAK/STAT.	JAK3
11021818	10.1016/S0002-9440(10)64629-9	2000	Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.	JAK3
10037026	10.3109/10428199909167389	1999	Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.	JAK3
10229324	10.1016/s0145-2126(98)00173-8	1999	Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.	JAK3
9990039	10.1073/pnas.96.4.1421	1999	Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation.	JAK3
9391124	10.1073/pnas.94.25.13897	1998	Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.	JAK3
9417042	10.1074/jbc.273.1.28	1998	Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid.	JAK3
9548458		1998	Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.	JAK3
9613975	10.3109/10428199809058353	1998	The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation.	JAK3
9613985	10.3109/10428199809058363	1998	Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine.	JAK3
9133417	10.1016/s1074-7613(00)80281-2	1997	Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells.	JAK3
9192639	10.1073/pnas.94.13.6764	1997	Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.	JAK3
8639867		1996	Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia.	JAK3
8660809	10.1006/cimm.1996.0143	1996	Evidence for a role of phosphatidylinositol 3-kinase in IL-4-induced germline C epsilon transcription.	JAK3
8689406		1996	Role of kinases in HTLV-I transformation.	JAK3
8756628	10.1128/MCB.16.9.4710	1996	A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9.	JAK3
8799169	10.1073/pnas.93.17.9148	1996	Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.	JAK3
